public health or access to essential medicines and that, in this regard, the TRIPs Agreement has to be subservient to other values and authorities, as is implicit in the Doha Declaration; 9. Agrees with the Commission that the World Health Organisation could play an important role, but warns that the autonomy and authority of the WHO should not be compromised; in this context encourages the Commission to consider the WHOâ€™s proposal for a solution to paragraph 6, presented to the TRIPs Council on 17 September 2002; 10. Considers that when conflicts arise, as they certainly will in this case, between intellectual property rights and public policy questions, they should always be resolved for the benefit of people and not patents. Further, underlines that there is a timetable laid down in the TRIPs Agreement for overall review of its workings, which has not been met, and notes that this process is also stalled in Geneva; 11. Asks the Commission and the Member States to support a broader discussion under the auspices of the WHO on how the TRIPs agreement affects the availability of affordable generic medicines; 12. Asks the Commission also to investigate alternative strategies for addressing the issue of the lack of product development for neglected diseases and to support the WHO in including this issue on its agenda; 13. Instructs its President to forward this resolution to the Council, the Commission, the Member States, the WTO, the WHO and the UN Secretary-General.